207 results on '"Ehlken B"'
Search Results
2. Burden of pulmonary arterial hypertension in Germany
3. Krankheitskostenstudie bei Patienten mit atopischem Ekzem in Deutschland
4. Cost of atherothrombotic diseases—myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease—in Germany
5. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals
6. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months
7. Economic evaluation of maintenance treatment with tacrolimus 0·1% ointment in adults with moderate to severe atopic dermatitis
8. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
9. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany
10. Cost of chronic plaque psoriasis in Germany: an analysis from the patient and payer perspectives
11. Bavarian Emesis and Nausea Economic Study: Chemotherapy-induced nausea and vomiting (CINV) in Munich, Germany
12. Cost of illness of severe haemophilia patients with inhibitors — results of a feasibility analysis in France and Germany
13. P.828 Characterisation of lisdexamfetamine dimesylate use in children, adolescents and adults in Europe
14. DRUG UTILIZATION STUDY FOR AZILSARTAN MEDOXOMIL IN GERMANY
15. Treatment Outcomes Following Initiation of Dapagliflozin or Basal Supported Oral Therapy Among Type 2 Diabetes Patients In Primary Care Practices In Germany
16. Impact of Comorbidities on the Cost of Depression Drug Therapy in General Practices in Germany
17. Drug Utilization Pattern of Lisdexamfetamine Dimesylate in Europe
18. Evaluation of resource utilization and related cost
19. Which Adverse Effects Influence the Dropout Rate in Selective Serotonin Reuptake Inhibitor (Ssri) Treatment?
20. Current Guidance for Brca Mutation Testing in Ovarian Cancer Patients
21. Treatment Discontinuation In Patients With Urinary Incontinence Suffering From Glaucoma
22. a Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals
23. PDB12 - Treatment Outcomes Following Initiation of Dapagliflozin or Basal Supported Oral Therapy Among Type 2 Diabetes Patients In Primary Care Practices In Germany
24. PMH20 - Impact of Comorbidities on the Cost of Depression Drug Therapy in General Practices in Germany
25. Rotavirus-Gastroenteritis im Säunglings- und Kleinkindes Alter : Ergebnisse einer prospektiven Erfassung in den Regionen Genf und Basel 1997/1998 (RoMoS)
26. Burden of Actinic Keratosis in Germany-Results of a Literature Research
27. Cost of Influenza in Germany
28. The Disease Burden of Influenza in Germany
29. Methodological Challenges in Comparing Topical Therapies in Dermatology in the Absence of Head to Head Studies
30. Roflumilast in Kombination mit langwirksamen Bronchodilatatoren in der Versorgung von Patienten mit schwerer und sehr schwerer COPD
31. PUK23 Burden of Chronic Kidney Disease in German Diabetes Patients, a Systematic Literature Review and Data Gap Analysis
32. PND26 Treatment Patterns and Resource Consumption in Patients With Multiple Sclerosis (MS)-Related Spasticity in Germany - Results of Move 1 Study
33. The Impact of the MS-CARE Patient Management Program on Adherence and Healthcare Costs in Interferon-beta Treated Patients with Multiple Sclerosis (P06.193)
34. Prospective study on acute lower respiratory tract infection in German children younger than 3 yeas (PRI.DE)
35. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany
36. PCV117 Clinical and Patient-Reported Outcomes of Triple Combination of Olmesartan Medoxomil (OM), Amlodipine Besylate (AML) and Hydrochlorothiazide (HCT) in Hypertensive Patients
37. PCV104 Persistence in Hypertension Treatment with Olmesartan Medoxomil Versus Valsartan - Analysis of Real-Life Prescription Data in Germany
38. Bluthochdrucksenkende Therapie mit freien und fixen Kombinationen aus Sartanen plus Amplodipin oder Hydrochlorothiazid – Behandlungsmuster und Persistenz bei Patienten mit Diabetes mellitus Typ 2
39. PCV59 PERSISTENCE AND COMPLIANCE IN HYPERTENSIVE PATIENTS TREATED WITH FIXED OR UNFIXED COMBINATIONS OF ANGIOTENSIN RECEPTOR BLOCKERS, AMPLODIPINE AND HYDROCHLOROTHIAZIDE
40. PCV62 PERSISTENCE AND COMPLIANCE IN HYPERTENSION TREATMENT WITH OLMESARTAN MEDOXOMIL – ANALYSIS OF REAL-LIFE PRESCRIPTION DATA
41. PMH45 - Drug Utilization Pattern of Lisdexamfetamine Dimesylate in Europe
42. PCN47 CHANGE OF ANTIFUNGAL TREATMENT PATTERNS AND ASSOCIATED COSTS IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) AFTER CHEMOTHERAPY IN A GERMAN HOSPITAL FROM 2004 TO 2006
43. PCN67 MANAGEMENT OF MALIGNANT ASCITES IN GERMANY—TREATMENT PATTERNS, RESOURCE CONSUMPTION, AND COSTS
44. PCV33 A LIFE-LONG COST-EFFECTIVENESS MARKOV MODEL COMPARING HIGH-DOSE VERSUS STANDARD DOSE STATIN THERAPY IN ACUTE CORONARY SYNDROME PATIENTS
45. PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE
46. PCV24 BUDGET IMPACT OF GUIDELINE ADHERENT THERAPY IN ACUTE CORONARY SYNDROME (ACS) IN GERMANY
47. PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES—RESULTS OF A PILOT STUDY
48. Costs related to febrile neutropenia (FN) in patients with acute leukemia (AL) or in autologous stem cell transplantation (ASCT) recipients treated in German hospitals
49. Cost analysis of febrile neutropenia (FN) management in three tumour types in Germany
50. PSS23 PROACTIVE USE OFTACROLIMUS 0.03% OINTMENT IN CHILDREN WITH MODERATE OR SEVERE ATOPIC DERMATITIS-OUTCOMES AND COST
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.